MetaVia completes extended Phase 1 study of DA-1726
+1 new source since this summary was written
MetaVia said on November 17, 2026 that the final participant completed the extended Phase 1 Part 3A study of DA-1726. The company extended dosing from 16 to 24 weeks, with participants receiving 48 mg weekly for the additional eight weeks. Previously reported Part 3B interim data showed a statistically significant 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss. MetaVia expects full Part 3A and 3B results in the first quarter of 2027 and is targeting a Phase 2 study in the second half of 2027.
Why it matters
The update advances DA-1726 toward Phase 2 development while leaving investors awaiting full safety and efficacy results. MetaVia plans a 48-week, non-biopsy Phase 2 study in up to 150 patients with MetALD and ALD, targeted to start in the second half of 2027.
Key facts
- 1MetaVia extended Part 3A treatment from 16 to 24 weeks, including an additional eight weeks at 48 mg of DA-1726 weekly. prnewswire.com
- 2Part 3B interim results showed a statistically significant 68.1% placebo-adjusted reduction in liver fat after 16 weeks. prnewswire.com
- 3Part 3B interim results also showed a 13.5% placebo-adjusted reduction in body weight. prnewswire.com
- 4MetaVia expects complete data from Parts 3A and 3B in the first quarter of 2027. sec.gov
- 5The planned Phase 2 study is designed to run for 48 weeks and include up to 150 patients with MetALD and ALD. sec.gov
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.